Salud financiera de hoja de balance de aTyr Pharma
Salud financiera controles de criterios 5/6
aTyr Pharma tiene un patrimonio de los accionistas total de $65.1M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $91.6M y $26.5M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$65.99m |
| Patrimonio | US$65.14m |
| Total pasivo | US$26.48m |
| Activos totales | US$91.62m |
Actualizaciones recientes sobre salud financiera
We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13
We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Recent updates
aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point
Sep 09We Think aTyr Pharma (NASDAQ:ATYR) Needs To Drive Business Growth Carefully
Jul 13We're Hopeful That aTyr Pharma (NASDAQ:LIFE) Will Use Its Cash Wisely
Feb 03Here's Why We're Not Too Worried About aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
Oct 04Here's Why We're Watching aTyr Pharma's (NASDAQ:LIFE) Cash Burn Situation
May 06We're Keeping An Eye On aTyr Pharma's (NASDAQ:LIFE) Cash Burn Rate
Jan 04aTyr Pharma rises on U.S. patent for anti-neuropilin-2 monoclonal antibodies
Sep 29aTyr Pharma stock rises on FDA fast track status for efzofitimod for lung disease
Sep 13aTyr Pharma gains with FDA Fast Track status for lead asset
Aug 11We Think aTyr Pharma (NASDAQ:LIFE) Needs To Drive Business Growth Carefully
May 10Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Jan 24aTyr Pharma: Successful Proof Of Concept In Pulmonary Sarcoidosis
Dec 28aTyr Stock Is Buoyant On Highly-Promising Lung Disease Data - Wait For Hype To Die Down And Buy
Sep 24Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
Sep 23Is aTyr Pharma (NASDAQ:LIFE) In A Good Position To Deliver On Growth Plans?
May 22aTyr Pharma, Inc. (NASDAQ:LIFE) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 25Did You Miss aTyr Pharma's (NASDAQ:LIFE) Impressive 103% Share Price Gain?
Feb 09
aTyr Pharma, Kyorin concludes subject visits for early-stage ATYR1923 trial in Japan
Jan 14ATyr Pharma's lead candidate meets safety endpoint in COVID-19 study
Jan 04aTyr Pharma concludes enrollment in mid-stage inflammatory lung diseases study
Dec 21aTyr Pharma (LIFE) Investor Presentation - Slideshow
Oct 31Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($76.3M) de ATYR superan a sus pasivos a corto plazo ($14.1M).
Pasivo a largo plazo: Los activos a corto plazo de ATYR ($76.3M) superan a sus pasivos a largo plazo ($12.4M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: ATYR está libre de deudas.
Reducción de la deuda: ATYR no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 39.6%.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: ATYR tiene menos de un año de cash runway basado en su flujo de caja libre actual.
Pronóstico de cash runway: ATYR dispone de suficiente cash runway para 1.1 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 18.1% cada año.